
Ivosidenib Has Preliminary Real-World Activity in IDH1-Mutated Cholangiocarcinoma
Ivosidenib (Tibsovo) displayed preliminary efficacy for the treatment of patients with IDH1-mutated cholangiocarcinoma in the real-world setting, according to data from the phase 3b ProvIDHe study (NCT05876754) presented during the 2025 ESMO …